aga2115
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 3, 2023 (NCT06086613)
Timeline
Indications
Studied for
Mechanism of action
- SclerostinINHIBITOR
SOST inhibitor
- Dickkopf-related protein 1INHIBITOR
DKK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07062588 | Phase 2 | Nov 30, 2025 | Angitia Incorporated Limited |
| NCT06086613 | Phase 1 | Oct 3, 2023 | Angitia Incorporated Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Angitia Incorporated Limited | For profit | 2 | 2 | 2 | 2023 |
1 organizations
Page 1 / 1